Afelimomab led to a modest mortality benefit in patients with severe sepsis and elevated interleukin-6 levels.docVIP

Available online at /content/9/5/E20 Evidence-Based Medicine Journal Club EBM Journal Club Section Editor: Eric B. Milbrandt, MD, MPH Journal club critique Afelimomab led to a modest mortality benefit in patients with severe sepsis and elevated interleukin-6 levels Eliseo Rondon1 and Ramesh Venkataraman2 1 2 Clinical Fellow, Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA Assistant Professor, Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA Published online: 5